Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials (Q37626194)

21 August 2017

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials (English)

1 reference

21 August 2017

phase I clinical trial

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Charles Ferté

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Marianna Fernandez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Antoine Hollebecque

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Serge Koscielny

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Antonin Levy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Christophe Massard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Rastislav Balheda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Carlos Gomez-Roca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Samy Ammari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jean-Charles Soria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

15 November 2013

1 reference

21 August 2017

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

246-252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

7 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

We should desist using RECIST, at least in GIST.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Analysis of survival by tumor response.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Tumor assessment criteria in phase I trials: beyond RECIST.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

A Time to Keep and a Time to Cast Away Categories of Tumor Response

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947306

Tumour growth rates and RECIST criteria in early drug development

1 September 2018

1 reference

12 December 2020

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

12 December 2020

Response rates, survival, and chemotherapy trials

1 reference

12 December 2020

Reporting results from chemotherapy trials. Does response make a difference in patient survival?

1 reference

12 December 2020

10.1158/1078-0432.CCR-13-2098

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

24240109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24240109%20AND%20SRC:MED&resulttype=core&format=json